| Literature DB >> 18940219 |
Thomas C Greenough1, Coleen K Cunningham, Petronella Muresan, Margaret McManus, Deborah Persaud, Terry Fenton, Piers Barker, Aditya Gaur, Dennis Panicali, John L Sullivan, Katherine Luzuriaga.
Abstract
A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18940219 PMCID： PMC2845914 DOI： 10.1016/j.vaccine.2008.09.084
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641